318 related articles for article (PubMed ID: 27639384)
1. Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.
Motallebnezhad M; Younesi V; Aghebati-Maleki L; Nickho H; Safarzadeh E; Ahmadi M; Movassaghpour AA; Hosseini A; Yousefi M
Tumour Biol; 2016 Nov; 37(11):14841-14850. PubMed ID: 27639384
[TBL] [Abstract][Full Text] [Related]
2. Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells.
Younesi V; Nejatollahi F
Int Immunopharmacol; 2014 Dec; 23(2):624-32. PubMed ID: 25466271
[TBL] [Abstract][Full Text] [Related]
3. Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.
Zarei N; Fazeli M; Mohammadi M; Nejatollahi F
Breast Cancer Res Treat; 2018 Jun; 169(3):427-436. PubMed ID: 29411237
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and Apoptotic Effects of Novel Anti-ROR1 Single-Chain Antibodies in Hematological Malignancies.
Aghebati-Maleki L; Younesi V; Baradaran B; Abdolalizadeh J; Motallebnezhad M; Nickho H; Shanehbandi D; Majidi J; Yousefi M
SLAS Discov; 2017 Apr; 22(4):408-417. PubMed ID: 28328317
[TBL] [Abstract][Full Text] [Related]
5. Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells.
Nejatollahi F; Jaberipour M; Asgharpour M
Tumour Biol; 2014 Aug; 35(8):7887-95. PubMed ID: 24828011
[TBL] [Abstract][Full Text] [Related]
6. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.
Kusada Y; Morizono T; Matsumoto-Takasaki A; Sakai K; Sato S; Asanuma H; Takayanagi A; Fujita-Yamaguchi Y
J Biochem; 2008 Jan; 143(1):9-19. PubMed ID: 17956902
[TBL] [Abstract][Full Text] [Related]
8. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
[TBL] [Abstract][Full Text] [Related]
10. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
Esparís-Ogando A; Ocaña A; Rodríguez-Barrueco R; Ferreira L; Borges J; Pandiella A
Ann Oncol; 2008 Nov; 19(11):1860-9. PubMed ID: 18641009
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y; Zi X; Zhao Y; Mascarenhas D; Pollak M
J Natl Cancer Inst; 2001 Dec; 93(24):1852-7. PubMed ID: 11752009
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
Chakraborty A; Hatzis C; DiGiovanna MP
Breast Cancer Res Treat; 2017 May; 163(1):37-50. PubMed ID: 28236033
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
14. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
15. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth.
Li SL; Liang SJ; Guo N; Wu AM; Fujita-Yamaguchi Y
Cancer Immunol Immunother; 2000 Jul; 49(4-5):243-52. PubMed ID: 10941907
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.
Ye JJ; Liang SJ; Guo N; Li SL; Wu AM; Giannini S; Sachdev D; Yee D; Brünner N; Ikle D; Fujita-Yamaguchi Y
Horm Metab Res; 2003; 35(11-12):836-42. PubMed ID: 14710366
[TBL] [Abstract][Full Text] [Related]
18. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y; Zi X; Pollak M
Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
